Alzheimer's disease multivalent peptide vaccine - ProMIS Neurosciences
Latest Information Update: 28 Oct 2024
At a glance
- Originator ProMIS Neurosciences
- Class Alzheimer vaccines; Antidementias; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease(Prevention) in Canada
- 28 Jul 2024 Pharmacodynamics data from a preclinical studies in Alzheimer’s disease presented at the Alzheimer's Association International Conference, 2024 (AAIC-2024)
- 25 Apr 2023 Pharmacodynamics data from preclinical studies in Alzheimer's disease released by ProMIS Neurosciences